1
|
Sandulache VC, Lei YL, Heasley LE, Chang M, Amos CI, Sturgis EM, Graboyes E, Chiao EY, Rogus-Pulia N, Lewis J, Madabhushi A, Frederick MJ, Sabichi A, Ittmann M, Yarbrough WG, Chung CH, Ferrarotto R, Mai W, Skinner HD, Duvvuri U, Gerngross P, Sikora AG. Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting. Oral Oncol 2019; 102:104440. [PMID: 31648864 DOI: 10.1016/j.oraloncology.2019.104440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2019] [Accepted: 10/01/2019] [Indexed: 01/17/2023]
Affiliation(s)
- V C Sandulache
- Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, United States; ENT Section, Operative Care Line, Michael E. DeBakey VA Medical Center, Houston, TX, United States.
| | - Y L Lei
- Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, United States
| | - L E Heasley
- Department of Craniofacial Biology, School of Dental Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States; Veterans Affairs Eastern Colorado Health Care System, Aurora, CO, United States
| | - M Chang
- Department of Radiation Oncology, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, United States
| | - C I Amos
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States
| | - E M Sturgis
- Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - E Graboyes
- Department of Otolaryngology Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, United States; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, United States
| | - E Y Chiao
- Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, United States; Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States
| | - N Rogus-Pulia
- Speech Pathology, University of Wisconsin School of Medicine, Madison, WI, United States; William S. Middleton Memorial Veterans Hospital, Madison, WI, United States
| | - J Lewis
- Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, United States
| | - A Madabhushi
- Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, United States; Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH, United States
| | - M J Frederick
- Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, United States
| | - A Sabichi
- Department of Medicine, Section of Hematology Oncology, Baylor College of Medicine, Houston, TX, United States; Medical Care Line, Department of Medicine, Section of Hematology/Oncology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States
| | - M Ittmann
- Department of Pathology, Baylor College of Medicine, Houston, TX, United States; Department of Pathology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States
| | - W G Yarbrough
- Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, United States
| | - C H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, United States
| | - R Ferrarotto
- Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Weiyuan Mai
- Department of Radiation Oncology, Baylor College of Medicine, Houston, TX, United States; Department of Radiation Oncology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States
| | - H D Skinner
- Department of Radiation Oncology, UPMC, Pittsburgh, PA, United States
| | - U Duvvuri
- Department of Otolaryngology Head and Neck Surgery, UPMC, Pittsburgh, PA, United States; ENT Section, Operative Care Line, Pittsburgh Veterans Affairs Medical Center, Pittsburgh, PA, United States
| | - P Gerngross
- Dental Service Line, Michael E. DeBakey VA Medical Center, Houston, TX, United States
| | - A G Sikora
- Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, United States; ENT Section, Operative Care Line, Michael E. DeBakey VA Medical Center, Houston, TX, United States.
| |
Collapse
|
2
|
Brooks HD, Glisson B, Lu C, Sabichi A, Johnson F, Ginsberg L, Bekele B, Papadimitrakopoulou V. Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6022] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6022 Background: Dasatinib is a potent inhibitor of src-family kinases, ephA2, PDGFR, Abl, and c-kit. A single-center, open-label, phase II trial was conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of dasatinib in recurrent or metastatic HNSCC. Methods: Pts with measurable disease by RECIST, who received 0 or 1 prior regimen for recurrent or metastatic HNSCC with an ECOG performance status 0–1 and tumor tissue appropriate for IHC and FISH were eligible. Dasatinib 100 mg bid was given for 28-day cycles. Primary endpoints were 12-wk progression-free survival (PFS) and objective response rate (ORR). Pts who took at least 1 dose of dasatinib and who died or left study before 12 wks were counted as progressive disease (PD). A 2 stage design, closure after accrual of 15 pts was required if PFS was 45% or less and ORR was 0. Otherwise, planned accrual was 35. Response was assessed at 4 and 12 wks. PK was studied in pts receiving dasatinib per PEG. Biomarkers relevant to Src pathway were planned in tissue and blood. Results: Fifteen pts were accrued. To date, 13 pts are evaluable for response, and 15 pts for toxicity. No grade 3/4 hematologic toxicities were noted. Grade 2–4 nonhematologic toxicities(n): pleural effusion(2), nausea/vomiting(2), dehydration(1), diarrhea(1), dyspnea(1). Toxicity led to hospitalization of 4 pts and drug discontinuation in 5 pts. ORR was 0. One pt was stable at 12 wks (PFS: 7.6%). This pt stopped drug at 15 wks due to toxicity, but also had PD. One pt died on study and cause was deemed unlikely related. Conclusions: Dosed at 100mg bid, dasatinib led to a characteristic toxicity profile in this pt population. Rates of hospitalization and discontinuation for toxicity were fairly high. Final efficacy parameters are pending evaluation of 2 pts. Evaluation of PK and tissue/blood biomarkers is ongoing. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - B. Glisson
- M. D. Anderson Cancer Center, Houston, TX
| | - C. Lu
- M. D. Anderson Cancer Center, Houston, TX
| | - A. Sabichi
- M. D. Anderson Cancer Center, Houston, TX
| | - F. Johnson
- M. D. Anderson Cancer Center, Houston, TX
| | | | - B. Bekele
- M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
3
|
Kim J, Wang X, Babaian R, Pisters L, Pettaway C, Wood C, Sabichi A, McDonnell T, Logothetis C, Troncoso P. A preoperative model evaluating the tissue effects of chemopreventive agents in low-volume prostate cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1007 Background: To identify and assess biomarkers modulated by prostate cancer chemopreventive agents, we created a model that, by exploiting the time between histologic diagnosis of prostate cancer and definitive therapy (prostatectomy), expedites tissue cross comparison and confronts the multifocality and multizonal heterogeneity of prostate cancer. Methods: Between February 2001 and April 2002, 48 presurgical patients were enrolled in a single-institution, randomized, double-blind trial of vitamin E (VE) and L-selenomethionine (SeMET) based on the framework of the ongoing Selenium and Vitamin E Cancer Prevention Trial. Patients were treated with 400 IU VE, 200 μg SeMET, a combination of VE and SeMET, or placebo for 3 to 6 weeks before prostatectomy. All patients also received a multivitamin and vitamin C 250 mg each day. Ex vivo simulated sextant biopsies on the radical prostatectomy specimen (RPS) were performed, and 36 of 39 evaluable patients had RPS sections that were suitable for pathologic evaluation. Blood components were collected at baseline and prior to prostatectomy. We derived an apoptotic index (AI) morphologically and a proliferation index (PI) by using immunohistochemistry and counting Ki-67-positive nuclei. Cells were counted and identified by cell type (normal and cancerous) and by zone (peripheral [PZ], transition [TZ], and central [CZ]). Results: In normal epithelial cells when the Wilcoxon rank sum test was used to compare AI and PI changes between groups, the AI was higher in the TZ than in the CZ, a difference independent of treatment effects (p = .01). Between the largest PZ and TZ tumor foci, a statistically significant difference in PI was observed (p = .006). Using a multiple linear regression model fitted for AI from the largest RPS PZ tumor focus, we found a statistically significant difference between the SeMET group and the placebo group (p = .02). Conclusions: Besides introducing new findings, the clinicopathologic model proved itself a platform for biomarker discovery by leveraging molecular technologies to full advantage, including serum protein profiling (Kim et al., CEBP 2005) and gene expression profiling of different cell types. Supported by NIH grant CA88761. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Kim
- UT M. D. Anderson Cancer Center, Houston, TX
| | - X. Wang
- UT M. D. Anderson Cancer Center, Houston, TX
| | - R. Babaian
- UT M. D. Anderson Cancer Center, Houston, TX
| | - L. Pisters
- UT M. D. Anderson Cancer Center, Houston, TX
| | - C. Pettaway
- UT M. D. Anderson Cancer Center, Houston, TX
| | - C. Wood
- UT M. D. Anderson Cancer Center, Houston, TX
| | - A. Sabichi
- UT M. D. Anderson Cancer Center, Houston, TX
| | | | | | - P. Troncoso
- UT M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
4
|
Kim ES, Kies M, Sabichi A, Ginsberg L, Burke B, Holsinger C, Feng L, Truong MT, Glisson B, Hong WK. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5546] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - M. Kies
- MD Anderson Cancer Ctr, Houston, TX
| | | | | | - B. Burke
- MD Anderson Cancer Ctr, Houston, TX
| | | | - L. Feng
- MD Anderson Cancer Ctr, Houston, TX
| | | | | | | |
Collapse
|
5
|
Kies MS, Sturgis E, Sabichi A, Blumenschein G, Glisson B, Garden AS, Burke B, Lewin JS, Barringer D, El-Naggar AK. Induction chemotherapy followed by surgical resection for young patients with squamous sell carcinoma of the oral tongue (SCC/T). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5515] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. S. Kies
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | - E. Sturgis
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | - A. Sabichi
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | | | - B. Glisson
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | | | - B. Burke
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | | | | | | |
Collapse
|
6
|
Sneige N, Lagios MD, Schwarting R, Colburn W, Atkinson E, Weber D, Sahin A, Kemp B, Hoque A, Risin S, Sabichi A, Boone C, Dhingra K, Kelloff G, Lippman S. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol 1999; 30:257-62. [PMID: 10088542 DOI: 10.1016/s0046-8177(99)90002-3] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Several studies have shown an association between high nuclear grade or necrosis of ductal carcinoma in situ (DCIS) lesions and the risk of local disease recurrence in patients with DCIS treated surgically with less than mastectomy. Although criteria for separating low from high nuclear grade lesions have been published, no information exists regarding interobserver reproducibility (IR). To assess IR in the classification of DCIS, six surgical pathologists from four institutions used the Lagios grading system to grade 125 DCIS lesions. Before meeting to evaluate the cases, a training set of 12 glass slides, including cases chosen to present conflicting cues for classification, was mailed to the participants with a written criteria summary. This was followed by a working session in which criteria were reviewed and agreed on. The pathologists then graded the lesions independently. The area of interest was marked on each slide before grading. After initial grading, the pathologists met again to resolve discrepant lesion classifications. A complete agreement among raters was achieved in 43 (35%) cases, with five of six raters agreeing in another 45 (36%) cases. In no case did two raters differ by more than one grade. The pairwise kappa agreement values ranged from fair to substantial (0.30 to 0.61). Generalized kappa value indicated moderate agreement (0.46, standard error = 0.02). Kappa statistics for the distinction between grades 1 and 2 and 2 and 3 were 0.29 and 0.48, respectively, (standard error = 0.02). Only one of the six raters differed significantly in scoring. With adherence to specific criteria, IR in the classification of DCIS cases can be obtained in most cases. Although these pathologists made a few grading system modifications, further refinements are needed, especially if grading will influence future therapy.
Collapse
Affiliation(s)
- N Sneige
- Department of Anatomic Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Lengye E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer M, Boyd D. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene 1995; 11:2639-48. [PMID: 8545121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
We undertook a study to determine if the serine-threonine kinase-encoding v-mos oncogene regulated the expression of the urokinase-type plasminogen activator. An expression vector encoding v-mos, but not a kinase-inactive mutant, stimulated urokinase promoter activity in CAT assays employing a squamous cell carcinoma cell line. The induction of urokinase promoter activity by v-mos was mediated, in part, via an increased AP-1 activity since (a) mutation of 2 AP-1 binding sites (at -1967 and -1885), or the co-expression of a transactivation domain-lacking c-jun mutant reduced the induction of the urokinase promoter by v-mos and (b) expression of v-mos increased the activity of a CAT reporter driven by three AP-1 tandem repeats. The stimulation of the urokinase promoter by v-mos was partially countered by co-expression of an ERK1/ERK2-inactivating phosphatase. Western blotting and zymographic analysis indicated that v-mos-transformed NIH3T3 cells (MSV NIH-3T3) secreted more urokinase compared with NIH3T3 cells and this was associated with a higher level of activated ERK1 and ERK2. Expression of a catalytically-inactive MAPKK mutant reduced the activity of a urokinase promoter-driven CAT reporter in the MSV NIH-3T3 cells. In conclusion, the data herein indicate that urokinase expression is regulated by v-mos through a MAPKK-dependent signaling pathway.
Collapse
Affiliation(s)
- E Lengye
- Department of Tumor Biology, MD Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | |
Collapse
|
8
|
Brown P, Seigfried J, Nader L, Chen T, Szabo E, Sabichi A, Preis L, Birrer M. Effects of a dominant-negative inhibitor of c-jun in lung cancer cell lines. Lung Cancer 1994. [DOI: 10.1016/0169-5002(94)90669-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Inghirami G, Foitl DR, Sabichi A, Zhu BY, Knowles DM. Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression. Blood 1991; 78:1503-15. [PMID: 1715792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Monoclonal antibodies (MoAbs) specific for autoantibody associated cross-reactive idiotypes (CRIs) frequently recognize the Igs of neoplastic B cells in patients with chronic lymphocytic leukemia (CLL) and/or Waldenstrom's macroglobulinemia. Very little is known regarding the normal B cells expressing CRIs (CRI-positive B cells). Using a variety of MoAbs against CRIs we investigated the distribution and topographic localization of CRI-positive B cells in normal adult human lymphoid tissues. We found that CRI-positive B cells represent a significant B-cell subpopulation expressing surface IgM (greater than 90%), IgG (approximately 5%), or IgA (approximately 2%). CRI-positive B cells are homogeneously distributed throughout all lymphoid tissues, accounting for 10% to 15% of all B lymphocytes, with the exception of the thymus, in which they represent the predominant B cell population. Immunophenotypic studies showed (1) that a small subpopulation (3.7% +/- 0.8%) of CRI-positive B cells are activated in vivo, based on CD25 and CD38 antigen expression; and (2) that approximately 50% of CRI-positive B cells express the 67-Kd pan-T-lymphocyte CD5 antigen, suggesting that the CRI-positive B-cell subset and the recently described CD5-positive B-cell subset are closely related. This hypothesis is supported by the fact that CRI-positive B cells produce oligo or polyreactive Igs, which are a characteristic feature of CD5-positive B cells, and also by the fact that both B-cell subpopulations appear to use similar and restricted Ig VH gene family members.
Collapse
Affiliation(s)
- G Inghirami
- Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY 10032
| | | | | | | | | |
Collapse
|